Immuron (IMRN) Non-Current Deferred Tax Liability (2022)

Immuron (IMRN) recorded quarterly Non-Current Deferred Tax Liability of $141141.4 in Q2 2022.

Immuron (IMRN) Non-Current Deferred Tax Liability (2022) Analysis & Trends

Immuron's Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $141141.4 for Q2 2022.

In Q2 2022, Non-Current Deferred Tax Liability changed N/A year-over-year to $141141.4; the TTM figure through Jun 2022 stood at $141141.4 (changed N/A YoY), while the FY2022 annual figure was $141141.4, changed N/A from the prior year.
Non-Current Deferred Tax Liability was $141141.4 for Q2 2022 at Immuron.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $141141.4 in Q2 2022 to a low of $141141.4 in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Immuron	921.61 Mn	921.58 Mn	-

Historic Data

Download Data

Date	Value
Jun 30, 2022	141,141.39
Jun 30, 2022	141,141.39